Combined inhaled salbutamol and mannitol therapy for mucus hyper-secretion in pulmonary diseases

AAPS Journal

Volumn 16, Issue 2, 2014, Pages 269-280

  Ong, Hui Xin ^a   Traini, Daniela ^a,d   Ballerin, Giulia ^a,b   Morgan, Lucy ^c,d   Buddle, Lachlan ^c   Scalia, Santo ^b   Young, Paul M ^a,d  

^a WOOLCOCK INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF FERRARA   (Italy)

^c Department of Microbiology and Infectious Diseases   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

cilia responce; epithelia transport; lung delivery; mannitol; salbutamol; smooth muscle responce

Indexed keywords

CYCLIC AMP; MANNITOL; MANNITOL SALBUTAMOL SULFATE; SALBUTAMOL SULFATE; UNCLASSIFIED DRUG;

AEROSOL; ARTICLE; BRONCHUS MUCOSA; CELL ASSAY; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG PENETRATION; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY; INHALATIONAL DRUG ADMINISTRATION; LUNG CLEARANCE; LUNG DISEASE; MOISTURE; MUCUS HYPERSECRETION; NOSE MUCOSA; PARTICLE SIZE; PHYSICAL CHEMISTRY; SCANNING ELECTRON MICROSCOPY; SMOOTH MUSCLE CONTRACTILITY; THERMAL ANALYSIS;

ADMINISTRATION, INHALATION; ALBUTEROL; BRONCHODILATOR AGENTS; CELLS, CULTURED; CILIA; DRUG THERAPY, COMBINATION; HUMANS; LUNG DISEASES; MANNITOL; MICROSCOPY, ELECTRON, SCANNING; MUCUS; MUSCLE, SMOOTH;

EID: 84895878772     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-014-9560-4     Document Type: Article

References (45)

1. Barker AF. Bronchiectasis. N Engl J Med. 2002;346(18):1383-93. (Pubitemid 34754612)
2. Murray TS, Egan M, Kazmierczak BI. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. Curr Opin Pediatr. 2007;19(1):83.
3. Barker AF, Couch L, Fiel SB, Gotfried MH, Ilowite J, Meyer KC, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med. 2000;162(2):481-5. (Pubitemid 30647187)
4. Geller DE. Aerosol antibiotics in cystic fibrosis. Respir Care. 2009;54(5):658-70.
5. Yang Y, Tsifansky MD, Shin S, Lin Q, Yeo Y. Mannitol-guided delivery of ciprofloxacin in artificial cystic fibrosis mucus model. Biotechnol Bioeng. 2011;108(6):1441-9.
6. Anderson P. Emerging therapies in cystic fibrosis. Ther Adv Respir Dis. 2010;4(3):177-85.
7. Wood AJJ, Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med. 1996;335(3):179-88. (Pubitemid 26249456)
8. Brannan JD, Anderson SD, Perry CP, Freed-Martens R, Lassig AR, Charlton B. The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a phase 3 comparison study with hypertonic (4.5%) saline. Respir Res. 2005;6(1):144.
9. Robinson M, Daviskas E, Eberl S, Baker J, Chan HK, Anderson S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J. 2001;14(3):678-85.
10. Hasani A, Toms N, O'Connor J, Dilworth J, Agnew J. Effect of salmeterol xinafoate on lung mucociliary clearance in patients with asthma. Respir Med. 2003;97(6):667-71. (Pubitemid 36675669)
11. Fazio F, Lafortuna C. Effect of inhaled salbutamol on mucociliary clearance in patients with chronic bronchitis. Chest. 1981;80(6 Suppl):827-30. (Pubitemid 12222772)
12. Bennett WD. Effect of β-adrenergic agonists on mucociliary clearance. J Allergy Clin Immunol. 2002;110(6, Supplement):S291-7. (Pubitemid 35471718)
13. Mortensen J, Hansen A, Falk M, Nielsen I, Groth S. Reduced effect of inhaled beta 2-adrenergic agonists on lung mucociliary clearance in patients with cystic fibrosis. CHEST J. 1993;103(3):805-11. (Pubitemid 23086179)
14. Robinson M, Bye PTB. Mucociliary clearance in cystic fibrosis. Pediatr Pulmonol. 2002;33(4):293-306. (Pubitemid 34273340)
15. Ong HX, Traini D, Bebawy M, Young PM. Epithelial profiling of antibiotic controlled release respiratory formulations. Pharm Res. 2011;28(9):2327-38.
16. Haghi M, Young PM, Traini D, Jaiswal R, Gong J, Bebawy M. Time-and passage-dependent characteristics of a Calu-3 respiratory epithelial cell model. Drug Dev Ind Pharm. 2010;36(10):1207-14.
17. Ong HX, Traini D, Salama R, Anderson SD, Daviskas E, Young PM. The effects of mannitol on the transport of ciprofloxacin across respiratory epithelia. Mol Pharm. 2013;10(8):2915-24.
18. Devalia J, Sapsford R, Rusznak C, Toumbis M, Davies R. The effects of salmeterol and salbutamol on ciliary beat frequency of cultured human bronchial epithelial cells, in vitro. Pulm Pharmacol. 1992;5(4):257-63. (Pubitemid 23017755)
19. Labiris N, Dolovich M. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Phamacol. 2003;56(6):588-99. (Pubitemid 37491710)
20. Adi H, Young PM, Chan H-K, Agus H, Traini D. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. Eur J Pharm Sci. 2010;40(3):239-47.
21. Haghi M, Traini D, Bebawy M, Young PM. Deposition, diffusion and transport mechanism of dry powder microparticulate salbutamol, at the respiratory epithelia. Mol Pharm. 2012;9(6):1717-26.
22. Palacio M, Cuffini S, Badini R, Karlsson A, Palacios S. Solid-state characterization of two polymorphic forms of R-albuterol sulfate. J Pharm Biomed Anal. 2007;43(4):1531-4.
23. Shariare M, de Matas M, York P. Effect of crystallisation conditions and feedstock morphology on the aerosolization performance of micronised salbutamol sulphate. Int J Pharm. 2011;415(1):62-72.
24. Begat P, Young PM, Edge S, Kaerger JS, Price R. The effect of mechanical processing on surface stability of pharmaceutical powders: visualization by atomic force microscopy. J Pharm Sci. 2003;92(3):611-20. (Pubitemid 36258976)
25. Heng D, Lee SH, Kwek JW, Ng WK, Chan H-K, Tan RB. Assessing the combinatorial influence of climate, formulation and device on powder aerosolization using the Taguchi experimental design. Powder Technol. 2012;226:253-60.
26. Tee S, Marriott C, Zeng X, Martin G. The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate. Int J Pharm. 2000;208(1):111-23.
27. Young PM, Edge S, Traini D, Jones MD, Price R, El-Sabawi D, et al. The influence of dose on the performance of dry powder inhalation systems. Int J Pharm. 2005;296(1):26-33. (Pubitemid 40693369)
28. Ong HX, Traini D, Young PM. Pharmaceutical applications of the Calu-3 lung epithelia cell line. Expert Opin Drug Deliv. 2013;0(0):1- 16.
29. Hirsh AJ. Altering airway surface liquid volume: inhalation therapy with amiloride and hyperosmotic agents. Adv Drug Deliv Rev. 2002;54(11):1445-62. (Pubitemid 35378659)
30. McDougall CM, Blaylock MG, Douglas JG, Brooker RJ, Helms PJ, Walsh GM. Nasal epithelial cells as surrogates for bronchial epithelial cells in airway inflammation studies. Am J Respir Cell Mol Biol. 2008;39(5):560.
31. Rutland J, Cole PJ. Nasal mucociliary clearance and ciliary beat frequency in cystic fibrosis compared with sinusitis and bronchiectasis. Thorax. 1981;36(9):654-8. (Pubitemid 12217360)
32. Andersen I, Camner P, Jensen PL, Philipson K, Proctor DF. A comparison of nasal and tracheobronchial clearance. Arch Environ Health. 1974;29(5):290-3.
33. Yaghi A, Zaman A, Dolovich MB. The direct effect of hyperosmolar agents on ciliary beating of human bronchial epithelial cells. J Aerosol Med Pulm Drug Deliv. 2012;25(2):88-95.
34. Daviskas E, Anderson SD, Eberl S, Chan HK, Young IH, Seale JP. Effects of terbutaline in combination with mannitol on mucociliary clearance. The Eur Respir J. 2002;20(6):1423-9. (Pubitemid 35460610)
35. Duchateau GS, Merkus FW, Zuidema J, Graamans K. Correlation between nasal ciliary beat frequency and mucus transport rate in volunteers. Laryngoscope. 1985;95(7):854-9. (Pubitemid 15032785)
36. Boek WM, Graamans K, Natzijl H, van Rijk PP, Huizing EH. Nasal mucociliary transport: new evidence for a key role of ciliary beat frequency. Laryngoscope. 2002;112(3):570-3. (Pubitemid 34225879)
37. Anderson SD, Brannan J, Spring J, Spalding N, Rodwell LT, Chan K, et al. A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol. Am J Respir Crit Care Med. 1997;156(3):758-65. (Pubitemid 27396412)
38. Leuppi JD, Brannan JD, Anderson SD. Bronchial provocation tests: the rationale for using inhaled mannitol as a test for airway hyperresponsiveness. Swiss Med Wkly. 2002;132(13/14):151-8. (Pubitemid 34606216)
39. Fujimoto N, Zhao C, Shichi H. The effects of prostaglandins E2 and F2α on porcine ciliary muscle cells in culture. Curr Eye Res. 1995;14(12):1155-63. (Pubitemid 26008860)
40. Ma X, Cheng Z, Wang Y, Unruh H, Stephens NL, Laviolette M. Changes in biophysical and biochemical properties of single bronchial smooth muscle cells from asthmatic subjects. Am J Physiol Lung Cell Mol Physiol. 2002;283(6):L1181-9. (Pubitemid 35379249)
41. Pang I-H, Shade DL, Tamm E, DeSantis L. Single-cell contraction assay for human ciliary muscle cells. Effect of carbachol. Invest Ophthalmol Vis Sci. 1993;34(5):1876-9. (Pubitemid 23120263)
42. Oldenburg PJ, Wyatt TA, Sisson JH. Ethanol attenuates contraction of primary cultured rat airway smooth muscle cells. Am J Respir Cell Mol Biol. 2010;43(5):539-45.
43. Govindaraju V, Michoud M-C, Ferraro P, Arkinson J, Safka K, Valderrama-Carvajal H, et al. The effects of interleukin-8 on airway smooth muscle contraction in cystic fibrosis. Respir Res. 2008;9(1):76.
44. Kume H, Hall IP, Washabau RJ, Takagi K, Kotlikoff MI. Beta-adrenergic agonists regulate KCa channels in airway smooth muscle by cAMP-dependent and -independent mechanisms. The J Clin Investig. 1994;93(1):371-9.
45. Salathe M. Effects of β-agonists on airway epithelial cells. J Allergy Clin Immunol. 2002;110(6):S275-81. (Pubitemid 35471716)